Keyword: Flagship Pioneering
As Flagship officially launches Cygnal, the startup is filling in some details, including how its tech works and where it wants to go beyond cancer
Omega Therapeutics is working on treatments that adjust gene expression up or down without making permanent changes to the genome.
Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”
Paul-Peter Tak joins Kintai Therapeutics as it steers its “precision enteric medicines” toward the clinic, with the first trials slated to start in 2020.
The goal is to genetically modify and differentiate stem cells to create cell therapies that are cloaked from the immune system.
Flagship Pioneering has raised $824 million for a fund to support biotech and health companies that have come up through its Flagship Labs foundry.
The ex-Roche SVP and Beigene founder will lead the Flagship startup as it builds a pipeline of cancer drugs targeting the peripheral nervous system.
Sigilon Therapeutics is bringing on Bioverativ’s chief global therapeutic operations officer, Rogerio Vivaldi, M.D., to serve as its CEO.
Microbiome developer Kaleido Biosciences has raked in $101 million in financing, after coming out of stealth last September with $65 million.
The Flagship Ventures-backed microbiome startup has the strong support of its existing investors, who will contribute $40 million to the IPO.